Description

1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo3.1.0hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, (1.alpha.,5.alpha.,6.alpha.)- is a high-purity, complex heterocyclic compound primarily utilized as a critical pharmaceutical intermediate. Its value lies in its role as a key building block for the synthesis of advanced antibacterial agents, particularly fluoroquinolone-class antibiotics. This product is essential for research institutions, contract development and manufacturing organizations (CDMOs), and active pharmaceutical ingredient (API) manufacturers focused on developing novel anti-infective therapies.

Application

• Pharmaceutical Intermediate: A key precursor in the synthesis of novel fluoroquinolone antibiotics.
• Antibacterial Drug Research: Used in R&D for developing new compounds targeting resistant bacterial strains.
• Active Pharmaceutical Ingredient (API) Synthesis: Serves as a core structural component in multi-step API manufacturing processes.
• Process Chemistry & Scale-Up: Employed in route scouting, optimization, and pilot-scale production for new drug candidates.
• Reference Standard: Can be supplied as a high-purity standard for analytical method development and quality control.
• Biochemical Research: Used in studies investigating the mechanism of action of topoisomerase inhibitors.

Basic Information

Product Name	1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo3.1.0hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, monohydrochloride, (1.alpha.,5.alpha.,6.alpha.)-
CAS No.	146961-34-4
Molecular Formula	C₂₀H₁₇F₃N₄O₃·HCl
Molecular Weight	469.83 g/mol (Free base: 433.37 g/mol)
Synonyms	(1α,5α,6α)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid monohydrochloride; BMS-284756 Related Compound; Garenoxacin Intermediate; T-3811 Intermediate; 1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, hydrochloride (1:1), (1S,5R,6S)-; (1S,5R,6S)-7-(6-Amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid hydrochloride
EINECS	Contact for details

Quality Control

This pharmaceutical intermediate is manufactured under strict quality management systems. Every batch is subjected to comprehensive analytical testing, including HPLC for purity and identity confirmation, to ensure it meets exacting specifications for use in API synthesis. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting critical parameters such as assay, related substances, and residual solvents. Our quality commitment supports compliance with ICH guidelines and customer-specific requirements for drug substance manufacturing.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive) and should be handled under dry conditions to maintain stability and purity.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0%
Related Substances (HPLC)	Total impurities ≤2.0% Any single unknown impurity ≤0.5%
Water Content (KF)	≤1.0%
Residual Solvents (GC)	Complies with ICH Q3C

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.